Mebiopharm is conducting research and development in conjunction with universities and researchers all over the world in order to seek out and patent technologies and the seeds of new development. Based on those patents, they are able to activate a broad international network of researchers, pressing forward with work on preclinical trials and clinical development. The company's core technology consists of the application of liposome to DDS for the purposes of developing new drugs.